JP2020527044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527044A5 JP2020527044A5 JP2020501456A JP2020501456A JP2020527044A5 JP 2020527044 A5 JP2020527044 A5 JP 2020527044A5 JP 2020501456 A JP2020501456 A JP 2020501456A JP 2020501456 A JP2020501456 A JP 2020501456A JP 2020527044 A5 JP2020527044 A5 JP 2020527044A5
- Authority
- JP
- Japan
- Prior art keywords
- treg
- cd45rc low
- population
- culture medium
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 13
- 239000001963 growth medium Substances 0.000 claims 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 5
- 229960002930 sirolimus Drugs 0.000 claims 5
- 230000001363 autoimmune Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 rapamycin compound Chemical class 0.000 claims 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 claims 1
- 208000031951 Primary immunodeficiency Diseases 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 1
- 230000008938 immune dysregulation Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305939 | 2017-07-13 | ||
| EP17305939.5 | 2017-07-13 | ||
| PCT/EP2018/068882 WO2019012024A1 (en) | 2017-07-13 | 2018-07-12 | METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / - |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527044A JP2020527044A (ja) | 2020-09-03 |
| JP2020527044A5 true JP2020527044A5 (enExample) | 2021-08-12 |
Family
ID=59399380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501456A Pending JP2020527044A (ja) | 2017-07-13 | 2018-07-12 | ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210147801A1 (enExample) |
| EP (1) | EP3652306A1 (enExample) |
| JP (1) | JP2020527044A (enExample) |
| WO (1) | WO2019012024A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL288241B2 (en) * | 2012-06-11 | 2023-10-01 | Wilson Wolf Mfg Corporation | Improved cell culture methods for stress cell therapy |
| US20220168394A1 (en) * | 2019-04-23 | 2022-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing or restoring immune tolerance |
| AU2021237790A1 (en) * | 2020-03-20 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric antigen receptor specific for human CD45RC and uses thereof |
| EP4565682A1 (en) * | 2022-08-04 | 2025-06-11 | Nantes Université | <sup2/>? <sub2/>?+? ?in vitro method for obtaining clinical-grade cd8cd45rc <ns1:sup>low/- </ns1:sup>?regulatory t cells |
| AU2024219048A1 (en) * | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US551413A (en) | 1895-12-17 | Willakd b | ||
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| WO1989007150A1 (en) | 1988-02-05 | 1989-08-10 | The Trustees Of Columbia University In The City Of | Retroviral packaging cell lines and processes of using same |
| JP3082204B2 (ja) | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス |
| US5023264A (en) | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
| US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
| US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| EP1201750A1 (en) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| US20030008923A1 (en) | 2001-06-01 | 2003-01-09 | Wyeth | Antineoplastic combinations |
| US7718196B2 (en) * | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| WO2012012797A2 (en) * | 2010-07-23 | 2012-01-26 | Indiana University Research And Technology Corporation | Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin |
| US10155025B2 (en) * | 2014-07-17 | 2018-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34 |
| AU2016290513B2 (en) * | 2015-07-03 | 2022-08-11 | Centre Hospitalier Universitaire De Nantes | Methods for obtaining regulatory T cells and uses thereof |
| CA2997646C (en) * | 2015-09-07 | 2024-04-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A new subpopulation of cd8+cd45rclow tregs and uses thereof |
-
2018
- 2018-07-12 WO PCT/EP2018/068882 patent/WO2019012024A1/en not_active Ceased
- 2018-07-12 EP EP18737628.0A patent/EP3652306A1/en not_active Withdrawn
- 2018-07-12 JP JP2020501456A patent/JP2020527044A/ja active Pending
- 2018-07-12 US US16/630,098 patent/US20210147801A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Watanabe et al. | CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells | |
| US10039788B2 (en) | Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection | |
| CA2446981C (fr) | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene | |
| ES2589311T5 (es) | Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos | |
| Zheng et al. | Transfer of regulatory T cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+ CD25+ cells in the recipient | |
| del Pilar Martínez-Montiel et al. | Therapy with stem cells in inflammatory bowel disease | |
| Brimnes et al. | Enteric bacterial antigens activate CD4+ T cells from scid mice with inflammatory bowel disease | |
| JP4628792B2 (ja) | 免疫疾患治療用ラパマイシン及びｉｌ−１０ | |
| Gille et al. | Chimeric antigen receptor (CAR) regulatory T-cells in solid organ transplantation | |
| JP2011528551A5 (enExample) | ||
| Roth‐Walter et al. | Immune modulation via T regulatory cell enhancement: Disease‐modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO) | |
| EP1993574B1 (fr) | Cellules t regulatrices cd4+cd25+ specifiques pour la greffe de cellules hematopoïetiques et la tolerance immunitaire | |
| CA2590401A1 (en) | Adoptive immunotherapy with enhanced t lymphocyte survival | |
| KR20200019231A (ko) | 조절 면역 세포를 제조하기 위한 방법 및 이의 용도 | |
| CN104245923A (zh) | 同种异型抗原-反应性调节t细胞的增殖 | |
| Guinan et al. | Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: a ONE Study consortium pilot trial | |
| Velardi et al. | Lymphokine production by T-cell clones after human bone marrow transplantation | |
| JP2020527044A (ja) | ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法 | |
| AU2009242297B2 (en) | Compositions for treating an inflammatory autoimmune condition | |
| US20170216417A1 (en) | Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases | |
| JP2008534620A (ja) | 制御性ｔ細胞を用いた移植組織の拒絶反応の防止 | |
| JP2021518130A5 (enExample) | ||
| Ciccocioppo et al. | Concise review: Cellular therapies: The potential to regenerate and restore tolerance in immune-mediated intestinal diseases | |
| Hall et al. | Changes in reactivity in vitro of CD4+ CD25+ and CD4+ CD25− T cell subsets in transplant tolerance | |
| Jin et al. | Large-scale in vitro expansion of human regulatory T cells with potent xenoantigen-specific suppression |